title: [Clinical study of cryoablation in the salvage treatment of stage III non-small cell lung cancer].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of argon-helium cryoablation as a salvage therapy for the failure cases of non-small cell lung cancer (NSCLC) after radiochemotherapy.
  
  
  METHODS
  A total of 12 NSCLC patients (stage III) with a diagnosis of recurrence after radiochemotherapy received cryoablation. The endpoint objectives were overall response rate (RR), clinical benefit rate (CBR), 1-year survival rate, quality of life (QOL) and safety profile.
  
  
  RESULTS
  Among them, the overall response rate was 6/12 cases and the clinical benefit rate 7/12 cases at 12 months post-cryoablation. The 1-year survival rate was 10/12 cases. No significant complications or adverse reactions occurred during the process of cryoablation. As shown by the QOL score, the quality of life was satisfactory.
  
  
  CONCLUSIONS
  As a salvage treatment for the recurrence NSCLC cases after radiochemotherapy, cryoablation may achieve a high response rate, a favorable 1-year survival rate and a high safety profile. It has excellent prospects for clinical applications.
authors.affiliation: Department of Interventional Therapeutics, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Li
authors.forename: Zhi
authors.initials: Z
authors.lastname: Guo
authors.forename: Hai-Tao
authors.initials: HT
authors.lastname: Wang
authors.forename: Fang
authors.initials: F
authors.lastname: Liu
authors.forename: Hong
authors.initials: H
authors.lastname: Ni
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000601:surgery*; D059248:Chemoradiotherapy; D003452:Cryosurgery; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016879:Salvage Therapy; D017211:Treatment Failure; D016896:Treatment Outcome